IRLAB update on clinical Phase II pipeline – IRL752 and IRL790

February 5, 2018

IRLAB’s two lead development programs, IRL752 and IRL790, both addressing complications in Parkinson’s disease, are progressing according to communicated plans and are both evaluated in Phase II following successfully concluded Phase I-studies. The promising results give a solid foundation for continued development of the both candidate drugs. In parallel, the development of large scale synthesis of API and quality assurance has been optimized for both IRL752 and IRL790.

For full press release, click here.
For Swedish version, click here.